Result: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

*Title*:

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis / Mike Wenzel [und weitere]

*Author/editor-in-chief*:

Wenzel, Mike (Verfasser)

*Published in*:

Prostate Cancer and Prostatic Diseases. - Basingstoke : Stockton Press, 30.05.2021. - Seite 139-148. - 10.1038/s41391-021-00395-4. - ISSN 1476-5608. - Jahrgang 25, Heft 2

*Publication*:

Basingstoke : Stockton Press, 30.05.2021

*Distribution*:

Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg

*Physical description scale*:

1 Online-Ressource (10 Seiten)

*Format*:

*eBook*

*Language*:

*eng*

*DOI*:

10.1038/s41391-021-00395-4

*oa_rights*:

Open Access
CC BY 4.0

*Result*: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

*Additional information*

*Additional functions*

Result: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Additional information

Additional functions